Table 1.
Base-case analysis results for 1 million of US adults aged 60+ years old previously vaccinated with ZVL, comparing no additional vaccination, vaccination with RZV, and ZVL revaccination.
| Outcome | No additional vaccination | Vaccination with RZV | ZVL revaccination | RZV vs no additional vaccination | RZV vs ZVL revaccination |
|---|---|---|---|---|---|
| Health Outcomes | |||||
| HZ cases | 176,801 | 94,033 | 161,474 | (82,769) | (67,441) |
| PHN cases | 20,173 | 11,771 | 17,908 | (8,402) | (6,137) |
| Other Complication cases | 27,098 | 15,152 | 25,090 | (11,946) | (9,938) |
| Ocular | 9,931 | 5,630 | 9,212 | (4,301) | (3,582) |
| Neurological | 8,926 | 4,807 | 8,203 | (4,119) | (3,396) |
| Cutaneous | 4,078 | 2,348 | 3,806 | (1,730) | (1,458) |
| Other non-pain | 4,163 | 2,368 | 3,870 | (1,796) | (1,502) |
| HZ-related deaths | 47 | 34 | 46 | (14) | (13) |
| Costs (discounted) | |||||
| Vaccination costs | – | $304,405,178 | $226,897,269 | $304,405,178 | $77,507,909 |
| Direct costs due to HZ | $325,979,303 | $162,986,740 | $291,629,995 | ($162,992,563) | ($128,643,255) |
| Indirect costs due to HZ | $72,960,889 | $27,579,322 | $60,934,650 | ($45,381,567) | ($33,355,328) |
| Total direct costs | $325,979,303 | $467,391,918 | $518,527,264 | $141,412,615 | ($51,135,346) |
| Total societal costs | $398,940,193 | $494,971,240 | $579,461,914 | $96,031,047 | ($84,490,674) |
| Life-years/QALYs (discounted) | |||||
| Life-years | 12,890,621 | 12,890,689 | 12,890,630 | 68 | 59 |
| QALYs | 10,120,248 | 10,121,881 | 10,120,694 | 1,633 | 1,187 |
| Cost-effectiveness | |||||
| Incremental cost per QALY gained | – | – | – | $58,793 | Cost saving |
–: not applicable; () refers to savings. HZ: herpes zoster; PHN: postherpetic neuralgia; QALY: quality-adjusted life-year; RZV: adjuvanted recombinant zoster vaccine; US: United States; ZVL: zoster vaccine live.